ClinicalTrials.gg

Program

HSK44459

A development code. Also written as “HSK44459 Cream”, “HSK44459 dose 1” and “HSK44459 dose 2”.

Its studies are mostly in Psoriasis · Idiopathic Pulmonary Fibrosis · Pulmonary Fibrosis · Dermatitis, Atopic, led by Haisco Pharmaceutical Group.

Furthest: phase 3, since Mar 25, 202610 company-led studies, 8 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haisco Pharmaceutical Group108 open or runningphase 3since Mar 25, 2026Aug 15, 2024Mar 2027phase 2 · NCT07623486

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 15, 2024First study: phase 1 study in HealthyFirst studyNCT06858657 · 82 enrolled · China
  2. Jan 6, 2025Phase 2 study in Idiopathic Pulmonary FibrosisNCT06764862 · 186 enrolled · China
  3. Mar 17, 2025Phase 2 study in Behcet's DiseaseNCT06902428 · 120 planned
  4. May 21, 2025Phase 2 study in Dermatitis, AtopicNCT06996912 · 150 enrolled · China
  5. Jun 5, 2025Phase 2 study in Idiopathic Pulmonary FibrosisNCT07019090 · 120 planned
  6. Jul 9, 2025Phase 2 study in Bechet's DiseaseNCT07070739 · 120 planned
  7. Aug 27, 2025Phase 2 study in PsoriasisNCT07150988 · 150 planned · China
  8. Mar 25, 20262 phase 3 studiesPhase 3 reachedNCT07503587, NCT07519070
  9. May 29, 2026Phase 2 study in PsoriasisNCT07623486 · 180 enrolled · China

Ahead

  1. Nov 6, 2026Primary completion: phase 2 study in PsoriasisNCT07150988
  2. Mar 2027Primary completion: phase 2 study in PsoriasisNCT07623486
  3. Jul 2027Primary completion: phase 2 study in Bechet's DiseaseNCT07070739
  4. Apr 5, 2028Primary completion: phase 3 study in IPFNCT07519070

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07623486Psoriasis · China2Active, not recruitingMar 2027180
NCT07519070IPF3Not yet recruitingApr 5, 2028420
NCT07503587Progressive Pulmonary Fibrosis3Not yet recruitingDec 30, 2028378
NCT07150988Psoriasis · China2Not yet recruitingNov 6, 2026150
NCT07070739Bechet's Disease2Not yet recruitingJul 2027120
NCT07019090Idiopathic Pulmonary Fibrosis2Not yet recruitingOct 31, 2026120
NCT06996912Dermatitis, Atopic · China2Active, not recruitingJan 20, 2026150
NCT06902428Behcet's Disease2Not yet recruitingJun 5, 2026120
NCT06764862Idiopathic Pulmonary Fibrosis · China2CompletedFeb 12, 2026186
NCT06858657Healthy · China1CompletedNov 18, 202482

How it is read

Names in the registry

  • “HSK44459”, 8 entries
  • “HSK44459 Cream”, 1 entry
  • “HSK44459 dose 1”, 1 entry
  • “HSK44459 dose 2”, 1 entry
  • “HSK44459 dose 3”, 1 entry

Codes read as this program: HSK44459.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
HSK44459 (Haisco Pharmaceutical Group): development program | ClinicalTrials.gg